SSSeppe Segers

Seppe Segers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seppe Segers has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Power, privilege and moral responsibility: learning from I.M. Young's Social Connection Model in the context of AI-driven healthcare

    by Brandon Ferlito, Michiel De Proost, Seppe Segers

    Artificial intelligence (AI) in healthcare is assumed to introduce risks that are not easily addressed by dominant philosophical models for thinking about responsibility. When an AI tool makes an error that results in patient harm, the question of who is responsible is rarely straightforward. Dominant models of responsibility work when harm can be traced to a single actor, but they fail in socio-technical systems where decisions and actions are distributed across multiple human and technological agents. Iris Marion Young’s social connection model of responsibility offers a systematic way to rethink responsibility in these contexts. Rather than locating responsibility solely after harms occur, Young proposes a forward-looking account that attaches responsibility to those who participate in and benefit from the structural processes that produce harm. Young’s framework organised around parameters of reasoning—power, privilege, interest, collective ability, and personal connection— provides an alternative way for understanding differentiated responsibilities across core actors in AI-driven healthcare.

  • Proceedings of the first European Ovary Workshop (EOW 2025), Lagos, Portugal, 17–20 February 2025

    by Christiani A Amorim, Susana M Chuva de Sousa Lopes, Michael Klutstein, Miguel Angel Brieño-Enriquez, Richard A Anderson, Francesca E Duncan, Michel De Vos, Pauliina Damdimopoulou, Pierre Comizzoli, Suzannah A Williams, et al.

    The inaugural European Ovary Workshop (EOW 2025), that was held on 17–20 February 2025, in Lagos, Portugal, brought together 165 scientists, clinicians, and early career researchers from 28 countries to advance ovarian biology from fundamental mechanisms to clinical translation. The program featured 12 scientific sessions, 17 keynote lectures, 15 selected short talks, 89 flash talks, and >90 posters spanning meiosis, folliculogenesis, ovarian reserve, aging, microenvironment, bioengineering, fertility preservation, environmental toxicology, wildlife conservation, patient-public involvement in science, and ethics. A comprehensive networking program combined formal and informal activities to stimulate scientific exchange and interaction across disciplines and career stages. Post-workshop feedback (n = 86) reflected high satisfaction with scientific content (rated 4.6/5), speaker quality (4.7/5), and networking (4.4/5), while identifying opportunities to expand clinical topics, diversify model organisms, and improve poster logistics. EOW 2025 established a unique community and a biennial platform to accelerate discovery and translation in ovarian research.

  • Open Access

    Problem of patient trust and sustainability: a care ethics response to Armitage

    by Michiel De Proost, Seppe Segers

  • The Anger Paradox: How Angry Should Physicians Be?

    by Sigrid Wallaert, Seppe Segers

    This article starts from the question: how angry should physicians be? Since the literature so far has mostly focused on patient anger, we endeavor to turn bioethical attention to physician anger instead. After specifying our central question in four different ways—in terms of its normativity, its use of the term “physicians,” the implied patient‐directed nature of this anger, and the difference between feeling and behaving angrily—we posit the anger paradox (AP) to help guide our argument. We discuss whether anger might damage the therapeutic relationship, or whether it could be a necessary expression of care. We follow three steps in looking at whether physicians can feel, should feel, or should express anger. We complicate the question of care and its objects by introducing Frankfurt's distinction between first‐ and second‐order desires. Finally, we look at the distinction between apt and appropriate anger, concluding that while physician anger can sometimes be apt, it is never appropriate to express toward patients.

  • Trapped in the promising role of digital twins?

    by Michiel De Proost, Brandon Ferlito, Seppe Segers


  • Speculation as an argument: artificial placenta technology, clinical translation, and the ethical debate about the ethical debate

    by Dorian Accoe, Clemence Van Ginneken, Seppe Segers

    Researchers developing artificial amnion and placenta technology (AAPT) regard this endeavor as one to enhance outcomes in neonatal intensive care units (NICU), by reducing mortality and morbidity for extremely premature neonates. While other applications can be imagined and have been the topic of ethical debate, there is discontent about bioethical considerations of potential AAPT applications beyond NICU praxis. Dismissed as ‘speculative’, the latter allegedly cloud ‘real’ ethical work necessary for clinical translation. This trope requires ethical attention, since it goes to the heart of bioethical praxis as an effort of studying emerging technologies like AAPT, and as a critical enterprise tethering ethical contemplation to empirics and uncovering value-ladenness of empirical ‘facts’. We explore different functions of speculation in ethics, after which we examine the main criticisms against the purported speculative implementation of AAPT. We then address how defining a practice as speculative reveals more about research priorities and biases, than about some quality of the practice. Labeling scenarios as ‘speculative’ seems to function as an argument in and of itself, rather than that an argument is provided for labeling certain scenarios as speculative, and why this matters. More: the ‘speculation argument’ can be extended to the translational aims of AAPT, its potential risks, and the assumed ‘benefits’ in terms of mortality and morbidity. Projections about ‘morbidity’ and ‘quality of life’ that do not start from insights and experiences of members of the disability community are precisely the type of speculation that should be questioned from a critical ethics perspective.

  • Open Access

    Stem cell-derived gametes: what to expect when expecting their clinical introduction

    by Ilse J de Bruin, Merel M Spaander, Simone Harmsen, Rosanne Edelenbosch, M Corrette Ploem, Nina Dartée, Madalena Cardoso Vaz Santos, Mathangi Lakshmipathi, Callista L Mulder, Ans M M van Pelt, et al.

    Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect—and investors to anticipate—the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including—but not limited to—safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.


  • Definitions as boundaries: Bioethics, Palestine and climate catastrophes

    by Dorian Accoe, Clemence Van Ginneken, Michiel De Proost, Seppe Segers